LadRx (NASDAQ:CYTR) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTRGet Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the stock.

LadRx Price Performance

Shares of CYTR opened at $0.09 on Tuesday. LadRx has a 12-month low of $0.05 and a 12-month high of $0.86. The firm has a 50-day moving average price of $0.10 and a 200 day moving average price of $0.12.

About LadRx

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

Read More

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.